Clinical Trial

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Study acronym: NEO-TIM
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-01-21; most recent amendment 2026-06-16.
Status change: Recruiting → Active, Not Recruiting 2023-09-12
Trial Details
NCT Number NCT04722575
Lead Sponsor Fondazione Melanoma Onlus
Collaborators: Clinical Research Technology S.r.l.
Conditions Melanoma
Enrollment 95 participants
Start Date 2020-12-03
Primary Completion 2023-12-15 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-18